MBX - MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc. Common Stock Logo

MBX - MBX Biosciences, Inc. Common Stock

https://mbxbio.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This Lionsgate Studios Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - APA ( NASDAQ:APA ) , Lionsgate Studios ( NYSE:LION )
Benzinga • 1 month, 1 week ago • score: 0.32
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wells Fargo analyst Omar Mejias initiated coverage on Lionsgate Studios Corp.
Bullish
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity - MBX Biosciences ( NASDAQ:MBX )
Benzinga • 2 months, 4 weeks ago • score: 0.29
GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX's novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, Ind., June 16, 2025 ( GLOBE NEWSWIRE ) -- MBX Biosciences, Inc.
Neutral
MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action - MBX Biosciences ( NASDAQ:MBX )
Benzinga • 8 months, 1 week ago • score: 0.09
On Tuesday, MBX Biosciences Inc. MBX revealed results from its Phase 1 single ascending dose and multiple ascending dose trial of MBX 1416 in healthy adult volunteers. MBX 1416 is the company's investigational long-acting glucagon-like peptide 1 ( GLP-1 ) receptor antagonist, being developed for ...
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana.

52W High
$27.50
52W Low
$4.81
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
1.77
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
3.10%
Institutions (25–75% balanced)
109.77%
Shares Outstanding
33,593,900
Float
14,610,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-6.23
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.56%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.8956
Previous
-0.8414
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025